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Abstract
Context: Patients with congenital adrenal hyperplasia (CAH) are chronically treated with
supraphysiological doses of glucocorticoids, which are known to induce insulin resistance.
Thiazolidinediones might reverse this effect and improve insulin sensitivity.
Objectives: To assess insulin sensitivity in CAH patients and the effect of pioglitazone treatment on
insulin sensitivity in CAH patients. Secondary objectives were the effects of treatment with pioglitazone
on blood pressure, body fat distribution, lipid, and steroid profiles.
Design: Randomized placebo controlled crossover trial.
Participants: Twelve CAH patients and 12 body mass and age-matched control subjects.
Intervention: Sixteen-week treatment with pioglitazone (45 mg/day) or placebo.
Main outcome measure: Insulin sensitivity measured by euglycemic clamp and oral glucose tolerance
test. Further measures were 24-h blood pressure profiles, body fat distribution measured by magnetic
resonance imaging, dual energy x-ray absorptiometry (DEXA) and bioimpedance procedures, liver fat
by magnetic resonance spectroscopy, lipid, and steroid profiles.
Results: CAH patients were insulin resistant compared with healthy controls. Treatment with
pioglitazone significantly improved insulin sensitivity in CAH patients (glucose infusion rate (GIR) from
28.5G11.6 to 38.9G11.0 mmol/kg per min, PZ0.000, GIR in controls 46.2G23.4 mmol/kg per min,
P!0.05 versus CAH). Treatment with pioglitazone decreased blood pressure (systolic: 124.0G13.6
vs 127.0G14.9 mmHg,P!0.001, diastolic: 72.8G11.5 vs 77.4G12.6 mmHg,P!0.001). No changes
in body fat distribution, lipid, and steroid profiles were observed.
Conclusions: CAH patients are insulin resistant compared with matched control subjects. Treatment
with pioglitazone improves insulin sensitivity and decreases blood pressure in CAH patients.
European Journal of Endocrinology 161 887–894
Introduction
Congenital adrenal hyperplasia (CAH) is an autosomal
recessive condition, which is in more than 95% of the
cases caused by a mutation in the gene for 21-hydroxyl-
ase (1). This defect results in increased secretion of
ACTH, adrenal hyperplasia and increased production
of androgens, but glucocorticoid deficiency. Current
treatment comprises glucocorticoid (and, if necessary,
mineralocorticoid) administration to prevent adrenal
crises and suppress the abnormal secretion of andro-
gens. However, because glucocorticoids are given in
slightly supraphysiological doses and the therapeutic
range for glucocorticoids is narrow, patients are at risk
of developing iatrogenic Cushing’s syndrome (1).
Glucocorticoids induce insulin resistance in humans
(2), and may precipitate diabetes in susceptible subjects.
Chronic exogenous or endogenous oversupply with
glucocorticoids is associated with changes in fat
distribution, typically toward more central/visceral fat.
Whether the observed insulin resistance is related to
these changes in body fat distribution is not known.
The use of supraphysiological doses of glucocorticoids
and androgen excess in CAH patients are associated
with the development of an unfavorable cardiovascular
risk profile (3). Data on the prevalence of cardiovascular
morbidity or life expectancy in CAH patients are not yet
available. In this respect, it is of interest that a recent
population-based study in Sweden has showed that
patients with Addison’s disease have a clearly increased
mortality rate. The excess mortality in both males and
females was for a major part caused by cardiovascular
disease. The authors of this study suggested that the
increased cardiovascular mortality in Addison’s
patients is caused by excess glucocorticoid exposure (4).
Of the few studies that have explored insulin
sensitivity in CAH, most have concluded that CAH
patients are indeed characterized by insulin resistance
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(5–11). Many different methods have been used to
assess insulin sensitivity, but studies using the eugly-
cemic hyperinsulinemic clamp method, the gold
standard to assess insulin sensitivity, are lacking.
It has also been reported that CAH patients are at risk
of developing other components of the metabolic
syndrome (3, 12, 13).
CAH patients are characterized by insulin resistance
and have an unfavorable cardiovascular risk profile, so
it might be a rational option to improve their insulin
sensitivity with insulin sensitizers. Improving their
cardiovascular risk profile might also improve their life
expectancy. Thiazolidinediones (TZDs) improve insulin
sensitivity in several conditions associated with insulin
resistance. The improvement of insulin sensitivity is
associated with beneficial changes in several para-
meters, like lipids, blood pressure, and vascular
function, and changes in inflammatory markers (14,
15). Therefore, TZDs might be a rational therapeutic
option in glucocorticoid-induced insulin resistance, as
has been suggested by earlier studies (16, 17). Such
improvement in insulin sensitivity might have a
twofold benefit: first, glucose tolerance in patients
with limited b-cell function will improve and hence the
chance to develop overt type 2 diabetes will decrease.
Secondly, cardiovascular risk factors associated with
insulin resistance will improve (18).
In the present study, we tested the hypotheses that
CAH patients who are chronically treated with
glucocorticoids are insulin resistant and that treatment
with pioglitazone improves insulin sensitivity in this
group. Insulin sensitivity was assessed using the
euglycemic clamp procedure. We also measured
the effect of pioglitazone treatment on body fat
distribution, including liver fat content, blood pressure,
and lipid profile.
Materials and methods
Patients
Adult subjects with biochemically and genetically
proven CAH on a stable corticosteroid replacement
dose for 3 months were included in the study.
Characteristics of the study population are shown in
Table 1. Gender, phenotype, results of mutation
analysis, medication, and mean salivary androstene-
dione levels of the study population are shown in
Table 2. Exclusion criteria were as follows: age !18
years, inability to give informed consent, significant
cardiovascular disease (defined as myocardial infarction
or stroke 6 months preceding the study), significant
renal disease (defined as a glomerular filtration rate
(GFR)!30 ml/min), significant liver disease (defined as
alanine aminotransferase and aspartate aminotransfer-
ase levels of more than three times the upper limit of
normal), and mental disease. All patients were fully
informed about the aim and design of the study and
all the methods involved. They consented with the
study protocol which was approved by the institutional
review board of the Radboud University Nijmegen
Medical Centre.
Insulin sensitivity in CAH patients treated with
glucocorticoids was compared to insulin sensitivity
measured in a group of body mass index (BMI) and
age-matched normal subjects. These subjects were
selected in a case–control design from a larger cohort
earlier described (19). Characteristics of the control
group are shown in Table 1.
Methods
At screening, all patients underwent a full physical
examination and electrocardiography. Blood was drawn
for determination of liver function and renal function.
To estimate GFR, the MDRD–GFR equation was used (20).
After a 4-week run-in phase, patients were random-
ized to treatment with either placebo for 16 weeks,
followed by pioglitazone (45 mg/day) for 16 weeks, or
treatment with pioglitazone for 16 weeks, followed by
placebo for 16 weeks in a randomized crossover design.
Patients visited the clinic every 2 months for medication
checks, adverse events, and measurement of weight,
blood pressure, and edema formation. Safety measures
included assessment of weight, blood pressure, and
edema. At the end of the respective study periods,
fasting glucose, lipid, and hormone levels (insulin,
ACTH, cortisol, aldosterone, renin, 17-OH progesterone
and androstenedione in serum, and 17-OH pro-
gesterone and androstenedione in saliva in the
morning, afternoon, and evening) were assessed and
insulin sensitivity was measured using a euglycemic
hyperinsulinemic (steady-state plasma insulin level
Table 1 Characteristics of patients and controls.
CAH patients Control subjects
Gender (M/F) 5/7 5/7
Age (years) 35.7G8.9 37.6G6.5
Height (m) 1.64G0.11 1.73G0.09
Weight (kg) 72.6G15.1 79.5G14.3
BMI (kg/m2) 26.9G4.7 26.6G5.1
Waist (cm) 87.1G10.7
Hip (cm) 101.3G10.5
Waist/hip 0.86G0.09
Systolic blood pressure (mmHg)
Supine 134G14 124G11
Upright 125G12
Diastolic blood pressure (mmHg)
Supine 83G8 78G12
Upright 87G11
Heart rate (bpm)
Supine 68G6 70G10
Upright 77G8
M, male; F, female; bpm, beats per minute.
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w600 pmol/l) clamp. Glucose tolerance was measured
using an oral 75-g glucose load. Blood glucose and
insulin samples were collected at 30, 60, 90, and
120 min after the test load. Glucose tolerance was
evaluated using the criteria of WHO (21). Body fat
distribution was assessed by two different methods,
magnetic resonance imaging (MRI) and DEXA scan-
ning. Total body DEXA scanning was performed using
a Hologic QDR 4500 densitometer (Hologic, Bedford,
MA, USA) to determine total bone mineral content
(BMC, g), total areal bone mineral density (g/cm2), fat
mass, and lean mass. Twenty-four-hour ambulatory
blood pressure measurement was performed using the
ambulatory SpaceLabs model 90207 blood pressure
monitoring system. Mean salivary androstenedione
levels were calculated from six samples: three samples
after placebo treatment and three samples after
pioglitazone treatment (same time points as after
placebo treatment). Undertreatment was defined as
the presence of a mean level of salivary androstenedione
above the upper reference morning (0800 h) level, i.e.
more than 0.63 nmol/l in males and 1.1 nmol/l in
females. Overtreatment was defined as the presence of a
mean level of salivary androstenedione below the lower
reference morning (0800 h) level, i.e. lower than
0.14 nmol/l in males and 0.16 nmol/l in females.
In control subjects insulin sensitivity was measured
using the same euglycemic hyperinsulinemic clamp
procedure as in CAH patients.
Procedures
Euglycemic clamp Experiments were performed in the
morning after an overnight (10 h) fast. Two i.v.
cannulae were inserted. One positioned retrogradely
into a dorsal vein of the hand that was placed in a
Plexiglas box, ventilated with heated air, for sampling of
arterialized venous blood (22). The second cannula was
inserted in an antecubital vein of the contralateral arm
for infusion of insulin and glucose. Insulin (Actrapid,
NovoNordisk, Bagsvaerd, Denmark; diluted in NaCl of
0.9% to a concentration of 1 U/ml, with the addition
of 2 ml whole blood per 50 ml) was infused at a rate of
60 mU/min per m2 body surface area (360 pmol/min
per m2). Arterialized venous plasma glucose was
measured in duplicate at 5-min intervals by the glucose
oxidation method (Beckman Glucose Analyser II,
Beckman, Fullerton, CA, USA). Plasma glucose was
clamped at the fasting level by a variable infusion of
glucose 20% solution. Plasma insulin was measured in
all samples with an in-house RIA at the start of the
clamp procedure and after 90 and 120 min (23). Whole
body glucose disposal was determined by glucose
infusion rate (GIR) as: (mean glucose infusion
90–120 min (mg/min)/weight (kg))!(1000/180 g/mol)
mmol/min per kg.
Magnetic resonance imaging and spectroscopy Liver
fat content and abdominal fat distribution were
determined by proton magnetic resonance spectroscopy
(MRS) and imaging (MRI) on a clinical 3T whole body
MR system (Siemens Magnetom Tim Trio, Erlangen,
Germany). All measurements were carried out during
breath-holding for 15 s. Liver fat content was
determined by single-voxel proton MR spectra with
STEAM localization (echo time 20 ms; repetition time
3 s). Hepatic fat percentage was calculated without
correction for differences in relaxation times by dividing
the lipid methylene signal intensity at 1.3 ppm by the
sum of the methylene lipid and water signal intensities
and multiplying the result by 100. Abdominal fat
distribution was derived from 16 T1-weighted FLASH-
2D axial MR images from a region extending from 4 cm
above to 4 cm below the fourth and fifth lumbar
interspaces. Subcutaneous and visceral fat volumes
were determined based on signal intensity.
Statistical analysis
For calculation and statistical analyses, the SPSS
personal computer software package was used (SPSS
Inc., Chicago, IL, USA) and P!0.05 was considered
statistically significant. Differences between pioglitazone
and placebo were statistically tested using Student’s
t-test or the Wilcoxon–Mann–Whitney test as appro-
priate. According to power calculations, detecting a
20% change in insulin sensitivity with a power of
80% at a significance level of 0.05 would require
11 subjects completing the study.
Results
A total of 12 CAH patients completed the study, seven
females and five males. All patients had a biochemically
and genetically proven CAH and were treated with
stable corticosteroid doses for at least 3 months. Eight
patients had the classic salt wasting type of CAH, three
patients had the classic simple virilizing type of CAH and
one patient had a nonclassical type of CAH. Evaluation
of mean salivary androstenedione levels showed that six
patients were adequately treated, five patients were
overtreated and one patient was undertreated (data
shown in Table 2).
Insulin sensitivity
CAH patients were insulin resistant compared with the
control group using the euglycemic clamp procedure
(GIR 28.5G11.6 vs 46.2G23.4 mmol/kg per min,
CAH patients versus controls respectively, PZ0.04,
Fig. 1). Similarly, the insulin sensitivity index in CAH
patients was significantly lower compared with control
subjects (0.35G0.16 vs 0.56G0.30 mmol/kg per min
(mU/l), PZ0.03).
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During treatment with pioglitazone, GIR significantly
increased compared with placebo treatment (38.9
G11.0 vs 28.5G11.6 mmol/kg per min, PZ0.000,
Fig. 1). Similarly, insulin sensitivity index improved
during pioglitazone treatment compared with placebo
(0.53G0.16 vs 0.35G0.16 mmol/kg per min (mU/l,
P!0.001) (24). A nonsignificant decrease in homeo-
stasis model assessment (HOMA)-estimated insulin
resistance (HOMA-IR) was observed after the use of
pioglitazone (1.97G1.40 vs 1.80G0.99, PZ0.34) (25).
Plasma glucose and insulin levels during the clamps
were similar during both treatments and in both groups.
Oral glucose tolerance test (OGTT) showed no signi-
ficant differences in glucose levels after the use of
pioglitazone compared to placebo. Insulin levels were
lower, although nonsignificantly, after the use of pioglita-
zone. The insulinAUC (mU/l per h) for the whole test period
(0–120 min) was significantly lower after the use
of pioglitazone compared with placebo (81G33 vs
111G69 mU/l per h, P!0.05), with no significant
difference in glucoseAUC (mmol/l per h) for the whole test
period (13.8G2.5 vs 13.1G3.1 mlU/l per h, PZ0.31).
Body fat distribution
The MRI–MRS data showed no statistically significant
changes in subcutaneous fat, visceral fat, the visceral–
subcutaneous fat ratio, and the percentage of liver fat
after the use of pioglitazone compared to placebo
(Table 3). Most patients had relatively low amounts of
liver fat. The only patients with a high liver fat content
during placebo (32.7%) showed a strong decrease in the
percentage of liver fat after the use of pioglitazone
(19.3%). Other patients did not show a decrease in the
percentage of liver fat after the use of pioglitazone.
DEXA scanning showed no relevant changes in total
body BMC, total lean mass, total fat mass, lean and fat
mass in trunk, arms and legs, and the distribution
of the fat mass after use of placebo or pioglitazone
compared to baseline data.
Blood pressure profiles
Ambulatory 24-h blood pressure was significantly
lower during pioglitazone compared with placebo
treatment (systolic: 124.0G13.6 vs 127.0
G14.9 mmHg, P!0.001, diastolic: 72.8G11.5 vs
77.4G12.6 mmHg, P!0.001, Fig. 2 and Table 4).
Clinical characteristics, lipid profile, and
steroid profile
Clinical characteristics, like weight, BMI, waist, hip, and
waist/hip ratio were not significantly different after the
use of placebo or pioglitazone. No significant changes in
lipid profile and levels of steroids, ACTH, and renin were
observed after the use of pioglitazone compared to placebo.
Discussion
The main findings of the present study are that CAH
patients who are chronically treated with glucocorti-
coids are insulin resistant as compared with body mass
and age-matched normal subjects and that treatment
with pioglitazone improves insulin sensitivity in this
group of patients.
The finding that CAH is associated with insulin
resistance is in line with earlier studies. These
prior studies suggest that both overproduction of
androgens and treatment with (supraphysiological
doses of) glucocorticoids can induce insulin resistance
(5–11, 26, 27).
In our study, we document a significantly lower
insulin sensitivity index and GIR in adult CAH patients
who were chronically treated with glucocorticoids. The
observed insulin resistance may well be the result of
treatment with glucocorticoids. Glucocorticoids are
known to induce insulin resistance, although the
mechanisms involved are incompletely understood
(28). Supraphysiological doses of glucocorticoids also
increase lipolysis and plasma free fatty acids (FFA),
which may lead to insulin resistance in muscles (16, 29).
Insulin resistance is known to be a risk factor for the
development of cardiovascular disease and to precede
Figure 1 Glucose infusion rate (GIR, mmol/kg per min) in control
subjects, CAH patients during placebo treatment and CAH patients
during pioglitazone treatment, measured during a euglycemic
clamp procedure. Mean values for each cluster are shown by the
different boxes.
Table 3 Magnetic resonance imaging–magnetic resonance spec-
troscopy measurements of fat distribution, during placebo or
pioglitazone in congenital adrenal hyperplasia patients.
Placebo Pioglitazone P value
Subcutaneous fat (l) 1.98G0.83 2.00G0.75 0.76
Visceral fat (l) 0.58G0.30 0.58G0.25 0.93
Visceral:subcutaneous
fat ratio
0.3G0.2 0.3G0.2 0.45
% Liver fat 4.2G9.0 3.6G5.6 0.65
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the development of type 2 diabetes (30, 31). Therefore,
CAH patients might be at risk to develop type 2
diabetes or cardiovascular disease later in life. Because
CAH patients need to continue glucocorticoid treatment
to suppress overproduction of androgens and as
substitution of cortisol, we reasoned that an interven-
tion with insulin-sensitizing drugs, like TZDs, might
have a favorable effect on insulin sensitivity in CAH
patients and as a result improve their cardiovascular
risk profile (15).
We observed a significant improvement of insulin
sensitivity (measured both by clamp and by insulin
response during OGTT) in CAH patients treated with
pioglitazone, although not to the level of the healthy
control group. Pioglitazone is known for its ability to
improve insulin sensitivity in several conditions associ-
ated with insulin resistance. It has been hypothesized
that TZDs have an insulin-sensitizing effect because of
alterations in adipokine release, which modulates
insulin sensitivity outside adipose tissue (15). TZDs
also promote the uptake and the storage of fatty acids
in adipose tissue, which does lead to an increase in
adipose tissue mass, but in this way TZDs spare other
insulin-sensitive tissues as the liver and the skeletal
muscle form the harmful metabolic effect of high
concentrations of FFA (15).
During pioglitazone treatment, ambulatory 24-h
systolic and diastolic blood pressures decreased signi-
ficantly. It has been noticed before that TZDs can
improve blood pressure profiles, although the exact
mechanism is not yet known. Insulin resistance is
known to be a risk factor for the development of
hypertension, so one may hypothesize that improve-
ment of insulin sensitivity may also decrease blood
pressure. Insulin resistance contributes to the develop-
ment of hypertension through several mechanisms like
angiotensin II and aldosterone actions, enhanced
sympathetic nervous system activity, dyslipidemia,
atherosclerosis, left ventricular hypertrophy and
changes in renal function and structure, like glomer-
ulosclerosis (32). The anti-hypertensive effects of
pioglitazone have been studied in Japanese male
patients with type 2 diabetes (33). This study showed
a significant decrease in mean blood pressure (109G14
to 101G10 mmHg) after 3 months of treatment with
pioglitazone (30 mg/day). Results of the present study
are in line with these findings. Anti-hypertensive
effects of pioglitazone have also been described in
type 2 diabetics with difficult-to-control hypertension,
nondipping diabetic patients, and in diet-induced obese
rats (34–36).
Although our study shows favorable effects of
pioglitazone on insulin sensitivity and blood pressure
in adult CAH patients, it has become uncertain whether
pioglitazone is a valuable addition to current treatment
strategies. Recent studies have questioned the long-term
safety of TZDs, especially with respect to long-term
cardiovascular outcome. Frequently noticed side effects
of TZDs include edema, weight gain, macular edema,
and heart failure. Furthermore, TZDs tend to increase
low-density lipoprotein cholesterol levels (37). Rosigli-
tazone may even be associated with a higher risk of
myocardial infarction and death due to cardiovascular
causes (38), but the RECORD study only confirmed the
increased risk of heart failure (39). The PROactive Study
showed favorable effects of pioglitazone on reduction of
all-cause mortality, nonfatal myocardial infarction, and
stroke in type 2 diabetes patients (40). Longer follow-up
of treatment with TZDs is needed to evaluate their
effects on congestive heart failure and cardiovascular
death (41). Treatment with TZDs also decreases bone
formation and bone mass, possibly as a result of
promoting adipogenesis above osteoblastogenesis (42).
This side effect seems particularly relevant in our group
of patients, against the background of the already
ongoing adverse effect of corticosteroids on the bone.
Over this short treatment period, we did not observe any
Table 4 Twenty-four-hour ambulatory blood pressure during
pioglitazone or placebo treatment in congenital adrenal hyper-
plasia patients.
Placebo Pioglitazone P value
24-h SBP 127.0G14.9 124.0G13.6 0.000
24-h DBP 77.4G12.6 72.8G11.5 0.000
24-h HR 77.1G13.9 75.1G13.5 0.007
24-h MAP 93.4G12.5 89.4G11.1 0.000
Daytime SBP 129.9G13.4 127.7G12.1 0.017
Daytime DPB 79.9G11.5 75.3G11.0 0.000
Daytime HR 78.9G12.9 78.1G12.9 0.396
Daytime MAP 95.9G11.3 91.9G10.3 0.000
Nighttime SBP 116.5G15.0 111.8G11.9 0.010
Nighttime DBP 68.3G12.6 62.6G9.2 0.000
Nighttime HR 70.2G13.3 66.6G10.0 0.048
Nighttime MAP 84.3G12.6 79.5G9.2 0.000
Nocturnal drop
in SBP (% fall)
10.7 12.2 0.341
Nocturnal drop
in DBP (% fall)
14.5 16.5 0.390
SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate;
MAP, mean arterial pressure.
Figure 2 Twenty-four-hour ambulatory blood pressure during
pioglitazone (open squares) or placebo treatment (closed squares)
in CAH patients.
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changes in BMC during treatment with pioglitazone.
Nevertheless, with the currently available data on
adverse effects of TZDs, the routine use of pioglita-
zone in CAH patients seems not to be indicated in a
clinical setting.
Our study has limitations. Inherent to the short
16-week treatment period, we were not able to evaluate
long-term effects of pioglitazone in our population.
Furthermore, insulin sensitivity was used as a surrogate
outcome, but no data on the prevalence of diabetes
mellitus or cardiovascular disease are available.
Furthermore, our study was probably underpowered
to detect changes in fat distribution, fat mass, and
liver fat.
In summary, this study shows that adult CAH
patients treated with glucocorticoids are insulin resist-
ant. Treatment with pioglitazone significantly improves
insulin sensitivity and decreases blood pressure in CAH
patients compared with the use of placebo. Despite these
findings, there is currently not enough evidence to
warrant the routine use of pioglitazone in this group
of patients.
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